Last reviewed · How we verify
NCT03381014
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors
trial testing Chemotherapy, Cancer, Anthracyclines in Chemotherapy Effect in 50 participants. Status unknown.
1 January 2019
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 January 2018 |
| Primary completion | 1 January 2019 |
| Estimated completion | 1 August 2019 |
Drugs / interventions tested
- Chemotherapy, Cancer, Anthracyclines — full drug profile →
Conditions studied
- Chemotherapy Effect — all drugs for Chemotherapy Effect →
Sponsor
Assiut University
Who can join
Adults 30 to 50, any sex, with Chemotherapy Effect. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early detection of cardiomyopathy in patients receiving Anthracycline chemotherapy and determine if speckle tracking echo and Troponin gene will add benefit for early detection of cardiomyopathy. Improve economic impact of oncologic patients from whom high sensitive troponin negative and normal speckle tracking patients can be safely excluded from long-term cardiac monitoring programs. To correlate between the molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathy
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03381014
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chemotherapy Effect
Currently open trials in the same condition.
- NCT06525402 — Effect of Sodium Bicarbonate, Saline and Black Mulberry Syrup on Degree of Oral Mucositis in Children Receiving Chemothe · NA · recruiting
- NCT06510010 — Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer · Phase 2 · recruiting
- NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
- NCT05864274 — Improve Cancer-related Cognitive Impairment · NA · recruiting
- NCT06863623 — The Effect of Immersive Virtual Reality and Relaxing Videos on Lung Cancer Patients · NA · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03381014 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 21 December 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03381014.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing